The changes in Refnot product label are approved. The new proposed idication of Refnot is added: as an immunomodulator indisseminated melanoma treatment.

For treatment of disseminated melanoma Refnot is injected subcutaneously in the dosage of 100,000 units once daily, five times a week (then a two-days pause) or in the dosage of 400,000 units once a day, three times a week (every other day) during 2-4 weeks before chemotherapy. It is possible to inject the drug subcutaneously in the dosage of 400,000 units into one or several places, it is better to interchange the injection points. When administered without the subsequent chemotherapy, Refnot in injected subcutaneously in the dosage of 100, 000 units once daily, five times a week (then a two-days pause) during four weeks. If the disease does not progress, the product injection may be continued.
Date: December 24, 2012

Back to the list